Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus …
RD Anderson, KG Griffy, D Jung, A Door, JD Hulse… - Clinical …, 1995 - Elsevier
Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus …
RD Anderson, KG Griffy, D Jung, A Door… - Clinical …, 1995 - clinicaltherapeutics.com
Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
[引用][C] Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency …
RD ANDERSON, KG GRIFFY, D JUNG… - Clinical …, 1995 - pascal-francis.inist.fr
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral
administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and …
administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and …
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus …
RD Anderson, KG Griffy, D Jung, A Door, JD Hulse… - Clinical …, 1995 - infona.pl
Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus …
RD Anderson, KG Griffy, D Jung, A Dorr… - Clinical …, 1995 - europepmc.org
Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus …
RD Anderson, KG Griffy, D Jung, A Dorr… - Clinical …, 1995 - pubmed.ncbi.nlm.nih.gov
Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …